Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.

Trial Profile

Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2013

At a glance

  • Drugs V 0191 (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2013 Planned number of patients changed from 210 to 200 as reported by European Clinical Trials Database.
    • 03 Jul 2012 Planned number of patients changed from 200 to 210 as reported by European Clinical Trials Database.
    • 19 Aug 2011 The trial was completed in Finland on 7 January 2010 and in Austria on 4 December 2009, according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top